Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of one randomized controlled trial. ^[1]
• Oral decitabine-cedazuridine demonstrated pharmacokinetic equivalence to intravenous decitabine, with he area under the curve (AUC) of oral therapy reaching 98.93% (90% confidence interval (CI) 92.66-105.60) of that for intravenous administration, indicating comparable decitabine exposure over 5 days.
• The study included patients with myelodysplastic syndromes or chronic myelomonocytic leukemia, and no significant differences in effectiveness outcomes were reported across various subgroups or population types.
• Oral decitabine-cedazuridine showed similar effectiveness to intravenous decitabine, establishing it as a viable alternative for the targeted patient populations.
• The most frequent Grade 3 or worse adverse events with oral decitabine-cedazuridine were thrombocytopenia (61%), neutropenia (57%), and anemia (50%), similar to the intravenous decitabine group.
• Serious adverse events (SAEs) were more common with oral decitabine-cedazuridine (31%) compared to intravenous decitabine (18%), and treatment-related deaths were slightly higher with intravenous decitabine (3 deaths) versus oral therapy (2 deaths).
• The study population included individuals aged 18 or older with myelodysplastic syndromes or chronic myelomonocytic leukemia, with an Eastern Cooperative Oncology Group performance status of 0 or 1 and a life expectancy of at least 3 months. No specific differences in effectiveness or safety were reported based on gender or race, though the population was predominantly male (65%) and White (91%).